Xilingyuan Pharmaceutical

Xilingyuan Pharmaceutical is a clinical-stage biopharmaceutical company based in Xi'an, China, focused on the discovery and development of innovative small molecule therapeutics. The company utilizes a specialized deuterium substitution technology platform to create differentiated drug candidates with optimized pharmacokinetic and safety profiles. Its primary therapeutic focus lies in metabolic diseases, particularly non-alcoholic steatohepatitis (NASH), and oncology. The lead candidate, XLY1588, is a selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 1 clinical development. By targeting validated biological pathways with improved molecular structures, Xilingyuan aims to deliver best-in-class treatments for patients with limited options.